Transdermal Drug Delivery Systems Market Size & Share 2023 to 2032

Transdermal Drug Delivery System Market Size

Transdermal Drug Delivery System Market size amassed over USD 29 billion in revenue in 2022. The industry is anticipated to witness over 8% CAGR between 2023 and 2032, owing to a  remarkable surge in incidences of chronic ailments.
 

expenditure on health and boosted investments in R&D projects focused on enhancing medicine and route of administration. For instance, the Centers for Disease Control and Prevention data suggests that chronic diseases are one of the prime drivers of annual healthcare costs of $4.1 trillion in the U.S. These factors, in line with the continuous technological developments in the drug delivery system, will augment market share.
 

In contrast, the limited number of approved medications and transdermal drug delivery systems worldwide may hamper industry performance. Also, the transdermal treatment route is not considered suitable as it may cause drug irritation or skin sensitivity, hindering the market landscape. Alongside the development, recall, and failure of a transdermal drug delivery system (TDDS) associate high costs, which may further act as a growth restraint over the forecast timeframe.
 

Transdermal Drug Delivery System Market Analysis

With respect to type, the transdermal patches segment of the transdermal drug delivery system market is expected to garner over USD 35.5 billion by 2032. Patches are classified into matrix patches, drug-in-adhesive patches, microneedle patches, and reservoir membrane patches. The increasing prevalence of several chronic conditions, such as cardiovascular diseases, cancer, and others, will supplement the market progress.
 

Transdermal drug delivery system market from the pain management segment is poised to record a valuation of over USD 19.5 billion by 2032. Opioid patches are extensively used in pain management applications, spurring market growth. Furthermore, the increasing prevalence of cancer, resulting in the accelerated embracing of pain patches.
 

Transdermal drug delivery system market from hospitals segment is likely to emerge as a major consumer of transdermal drug delivery systems, accounting for over USD 17 billion by 2032. A large patient population undergoing treatment for a variety of disorders will accelerate product adoption across hospital settings. Furthermore, the availability of a wide range of medical services in these establishments will transform business dynamics.
 

North America transdermal drug delivery system market accumulated over 46.% of revenue share in 2022 and is speculated to attain a healthy CAGR through 2032. Growing adoption of unhealthy lifestyles among individuals, such as alcohol consumption, smoking, and lack of exercise, will boost the disease rate, thereby fostering the market trends.
 

Transdermal Drug Delivery System Market Share

Key players in the transdermal drug delivery system market are:

• Novartis
• Mylan
• Amneal Pharmaceuticals Inc
• Zydus Pharmaceuticals, Inc
• UCB
• Hisamitsu Pharmaceutical Co Inc
• Corium Inc
• Micropoint Technologies
• Sparsha Pharma International Pvt. Ltd.,
• Luye Pharma.

Companies operating in this business vertical are indulging strategic associations and drug R&D projects to strengthen their market standing.
 

Impact of the COVID-19 pandemic

The COVID-19 pandemic had a damaging impact on the transdermal drug delivery system industry. The stringent lockdown measures implemented by numerous governments worldwide created a huge gap in product demand and supply, thus, resulting in a decline in the sales of transdermal drug delivery systems. Furthermore, reduced patient visits to the hospital due to delays and cancellation of elective medical procedures further limited product uptake, thus, impacting the trade dynamics during the crisis.
 

The transdermal drug delivery system market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

By Type

• Patches
  • Drug-In-Adhesive Patches
  • Matrix Patches
  • Reservoir Membrane Patches
  • Microneedle Patches
• Semisolids
  • Gels
  • Ointments
  • Sprays

By Application

• Pain Management
• Hormonal Applications
• Central Nervous System Disorders
• Cardiovascular Diseases
• Others

By End-use

• Hospitals
• Clinics
• Home Care Settings
• Others 

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Poland
  • Switzerland
  • The Netherlands
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Indonesia
  • Thailand
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Peru
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel